logo
logo

Hotspot Therapeutics Closes $100M Series C To Advance First-In-Class Allosteric Drug Discovery Platform To The Clinic

Nov 29, 2021•almost 4 years ago

Amount Raised

$100 Million

Round Type

series c

Boston

Description

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced the close of its oversubscribed $100 million Series C financing, bringing its total funding to $190 million.

Company Information

Company

Hot Spot Therapeutics

Location

Boston, Massachusetts, United States

About

HotSpot Therapeutics is targeting naturally occurring pockets on proteins called "natural hotspots" that are decisive in the control of cellular protein function. Largely unexploited by industry, these pockets are highly attractive for drug discovery and enable the systematic design of highly potent and selective small molecules that exhibit novel pharmacology. The company's Smart AllosteryTM technology platform utilizes AI-driven data mining of large and highly diverse data sets to identify pockets that matter on proteins, integrated with a tailored pharmacology toolkit and bespoke chemistry to rapidly deliver superior hotspot-targeted small molecules. The company has successfully exploited natural hotspots across multiple classes, including E3 ligases, kinases, and transcription factors. HotSpot has established a product pipeline of first-in-class small molecules for the treatment of cancer and autoimmune diseases, each enabled by precision and patient-targeted clinical design. To learn more, visit www.hotspotthera.com. SOURCE HotSpot Therapeutics

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech